Abstract

The new patented compounds are based on a potent reversible noncovalent mechanism of action, which is useful for treating MAGL-mediated diseases, such as neuroinflammation/degeneration, pain, multiple sclerosis/amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease.

Research Institution

Università di Pisa

Numero di pubblicazione

EP3889132B1

TRL

N.A.

Technologies, Systems, Applications

New drugs development